Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$17.78M+38.75%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark Strobeck
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 157
- Beta
- 1.64
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -7.56
Financials
Revenue
$17.78M+38.7%Net Income
$-1.17MEBITDA
$-399.0KFree Cash Flow
$1.46MEPS (diluted)
$-0.34Shares Outstanding (diluted)
3.96M+759.2%Operating Expenses
$4.30MCash & Debt
$24.80MReturn of Capital
$0.00Revenue by Segment (annual)
$2.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $69.26M | $-5.31M | $-1.50 |
| 2024 | $101.49M | $-480.0K | $-0.25 |
| 2023 | $83.61M | $-8.44M | $-3.60 |
| 2022 | $72.81M | $-18.68M | $-18.90 |
| 2021 | $61.93M | $-32.67M | $-38.30 |
| 2020 | $62.20M | $-30.89M | $-44.90 |
| 2019 | $61.30M | $-34.13M | $-56.10 |
| 2018 | $63.39M | $-32.13M | $-66.90 |
| 2017 | $57.30M | $-25.92M | $-56.10 |
| 2016 | $53.28M | $-19.80M | $-43.00 |
| 2015 | $55.35M | $-14.42M | $-31.90 |
| 2014 | $54.19M | $-21.33M | $-57.20 |
| 2013 | $52.38M | $-48.78M | $-163.20 |
| 2012 | $49.84M | $-54.02M | $-291.50 |
Valuation
RMTIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
107Social Signal Score
Mentions (3)
- Newsseekingalpha.com·53d ago·Positive
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·54d ago·Negative
Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates Rockwell Medical (RMTI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.5 per share a year ago.
View source ↗ - Newsbusinesswire.com·54d ago·Positive
Rockwell Medical Announces Second Quarter 2026 Results WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces Q2'26 results, delivering strong year-over-year growth, expanding gross margin and generating positive operating cash flow.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.13 per share
Typical surprise -44.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.34 vs $-0.23miss
- Thu, May 7$-0.40 vs $-0.10miss
- Thu, Mar 26$-0.10 vs $0.40miss
- Wed, Nov 12$-0.50 vs $-0.40miss
- Thu, Aug 14$-0.50 vs $-0.50beat
- Mon, May 12$-0.40 vs $-0.30miss
Estimates and results for RMTI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RMTI officers and directors.
- Bought
- $94k
- Sold
- $133k
30 trades
19 trades
- Hunter Heathersold
- Neri Jessesold
- Cooper John Gsold
- Hunter Heathersold
- Chole Timothysold
- Neri Jessesold
- Strobeck Marksold
- Chole Timothysold
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RMTI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.